COMMUNIQUÉS West-GlobeNewswire

AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
07/08/2025
VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for [...]
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
07/08/2025
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18 th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted [...]
BeautyHealth Reports Second Quarter 2025 Financial Results
07/08/2025
Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster LONG BEACH, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
07/08/2025
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis [...]
RxSight, Inc. Reports Second Quarter 2025 Financial Results
07/08/2025
ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
07/08/2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/08/2025
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development [...]
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
07/08/2025
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
07/08/2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction [...]
J-Star Holding Announces Closing of Underwriters’ Over-Allotment Option in Connection with Initial Public Offering
07/08/2025
TAICHUNG CITY, Taiwan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications [...]
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
07/08/2025
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti’s Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti [...]
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
07/08/2025
- Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 [...]
PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET
07/08/2025
MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion [...]
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
07/08/2025
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 August 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " [...]
SurgiBox Achieves CE Mark for SurgiField System Devices to Improve Access to Safe Surgery at the Point of Need
07/08/2025
CE Certification positions SurgiBox for global expansion and robust sales acceleration CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SurgiBox, a medical technology company committed to improving access to safe, [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
07/08/2025
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
07/08/2025
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen [...]
Genmab Announces Financial Results for the First Half of 2025
07/08/2025
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 [...]

Pages